NCT03103932Recruiting
Biomarker Guided Discharge of Heart Failure Patients
BiomarkeR cAndidates to Guide Discharge of Patients Admitted to Hospital With heARt Failure
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- First submitted
- 28 Mar 2017
- Start date
- 26 Aug 2017
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Heart failure
- NCT number
- NCT03103932
What you commit to
- Study type: Interventional
- Planned participants: 750
- From 26 Aug 2017 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who has participated in another research trial involving an investigational product in the past 30 days
Other illness
- Patient listed for heart transplant, or admitted specifically for transplant workup
- Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness
- Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's ability to participate in the trial
Lab values
- Patient with end stage organ failure
- Kidney: creatinine \>350 μmol/L or Estimated GFR ≤15 ml/min
- Liver dysfunction: liver function test \>2.5 times normal
- Lungs: pulmonary FEV1\<50% predicted
Other
- Patient unable to provide blood samples or cannot participate in follow-up
- Patient requiring intubation
- Patient with an admission NTproBNP measurement of \>30,000 pg/ml
- Patient in cardiogenic shock
Who the study is looking for
- Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.